Molson Coors Beverage Company

source: coverage-next-full ticker: TAP step: 01 title: Business Model & Overview retrieved: 2026-05-28

Step 01 — Business Model

1. Objective

Describe Molson Coors Beverage Company's business model: what it sells, to whom, through which channels, at what unit economics, and how it converts brand equity into cash.

2. Approach

Used 10-K segment descriptions, IR press releases, the brand portfolio cataloged from FY2025 filings, and competitive context from the industry overview file [S1][S2][S3].

3. Findings

What TAP Sells

A portfolio of beer and beyond-beer beverages spanning value, premium, above-premium, and non-alcoholic categories.

Core power brands (mass-premium light beer, mass-premium lager):

• Coors Light, Miller Lite, Coors Banquet (US)
• Molson Canadian, Coors Original (Canada)
• Carling (UK — largest-volume UK lager)
• Ožujsko (Croatia)
• Staropramen (Czech Republic / Central Europe — flagship)

Above-premium / premium portfolio:

• Blue Moon (US — Belgian-style wheat)
• Leinenkugel's Summer Shandy (US — seasonal)
• Madri Excepcional (UK — Spanish-style lager, now #2 UK on-premise lager by value [S3])
• Peroni Nastro Azzurro (UK distribution — note: TAP holds UK rights; Asahi owns Peroni globally)
• Pilsner Urquell (Central Europe heritage)

Beyond Beer (FMBs, hard seltzers, energy, mixers):

• Topo Chico Hard Seltzer (Coca-Cola JV, US)
• Simply Spiked (Coca-Cola JV, US)
• ZOA Energy (Dwayne Johnson minority-stake partnership)
• Fever-Tree US distribution (exclusive from Feb 1, 2025; 8.5% equity stake) [S4]
• Blue Run Spirits (acquired 2023; partial impairment 2025)

Value brands:

• Miller High Life, Keystone Light (US — value tier)

To Whom

• ~80% of revenue from Americas (US the dominant geography + Canada + LatAm)
• ~20% from EMEA&APAC (UK + Central/Eastern Europe primarily; small Asia presence) [S2]
• B2B customer base: independent beer distributors (US three-tier system), national grocery & C-store chains, on-premise bar/restaurant accounts. End-consumer is the eventual drinker; immediate customer is the distributor / retailer.

Through Which Channels

• Off-premise (grocery, C-store, club, drug): ~75–80% of US volume; price-elastic; competitive shelf-share battles
• On-premise (bars, restaurants, stadiums): ~20–25% of US volume; higher per-unit margin; brand-equity reinforcement role
• Three-tier system (US): Brewer → independent distributor → retailer. Distributors are TAP's economic moat partners — long contracts, geographic exclusivity, mutual investment in tap handles, signage, merchandising. The "12,000 new tap handles" cited post-Bud-Light shift is a distributor-investment metric [S3].

Unit Economics (FY2025 GAAP, with underlying flagged)

Value-Chain Layer Map

How It Makes Money

• Volume × Price × Mix model. Per-hectoliter net sales revenue (NSR/HL) is the master KPI. Volume declines have been offset for several years by pricing + mix shift (above-premium gaining mix share within a contracting overall pie).
• Net pricing 2025: in the +2% to +4% range across regions, with Americas +3–4% and EMEA&APAC +4–5% (constant currency) [S6]. Underlying EBITDA margin held ~21–22% on a 4% decline in net sales — pricing discipline.
• Beyond Beer is partnership-led and capital-light vs. building from scratch. Coca-Cola JV provides marketing reach for Topo Chico + Simply Spiked. Fever-Tree gives TAP the US non-alc-mixer beachhead at minority equity cost.

4. Risks & Counter-Evidence

• Distributor concentration risk: TAP depends on independent distributors. If a major distributor pivots commitment, share losses follow rapidly. The Bud-Light story cuts both ways — TAP captured share via distributor-channel choice, and could lose it via the same mechanism.
• Brand fade risk on light beer: Coors Light and Miller Lite are in a sub-category (mass-premium American light) facing the worst demographic + GLP-1 headwinds. Even with share gains, the addressable pie is shrinking.
• Beyond Beer is small: Despite headlines, beyond beer is a small fraction of revenue. Blue Run Spirits already partially impaired ($75.3M in Q3 2025). Topo Chico Hard Seltzer has not become the share leader many expected.

5. Decision / What I'm doing differently

Treat TAP as a brewer first, beyond-beer aspirant second. ~95% of the equity value comes from the core beer P&L. Beyond-beer is option value — meaningful for the multi-year story but not material to base-case 2026–2028 forecasts.

6. Open Questions

1. Will Madri-style above-premium creations work in the US, or is it a UK-specific phenomenon? Step 03 examines revenue mix evolution.
2. What is the actual unit-economics of the Coca-Cola JV — is TAP economics or marketing-and-distribution-only? Press releases not fully transparent.

7. Source Index

• [S1] TAP_financials/sec_filings/filing_inventory.md — FY2025 10-K
• [S2] TAP_financials/industry/competitive_landscape.md
• [S3] Fox Business — "Coors Light, Miller Lite combined sales now 50% bigger than Bud Light"
• [S4] BusinessWire — Fever-Tree partnership PR (Jan 30, 2025)
• [S5] TAP_financials/xbrl/xbrl_summary.md
• [S6] Molson Coors IR — Q4 2025 / FY2025 earnings release (Feb 18, 2026)

source: coverage-next-full ticker: TAP step: 04 title: Financial Snapshot & Adversarial Research Sweep retrieved: 2026-05-28

Step 04 — Financial Snapshot

1. Objective

Assess the quality of TAP's reported financials, identify accounting / one-time / impairment adjustments, and run the Adversarial Research Sweep for short-seller reports, investigations, lawsuits, and quality-of-earnings flags.

2. Approach

Cross-referenced the cached XBRL summary [S1], reviewed FY2025 impairment disclosures [S2], scanned for litigation / short reports / investigations [S3][S4], and benchmarked GAAP-vs-underlying reconciliation against company-disclosed methodology [S2].

3. Findings

Statement Quality — GAAP vs Underlying

The biggest single quality issue is the FY2025 impairment package: $3,645.7M Americas goodwill + $198.6M Staropramen brand + $75.3M Blue Run Spirits = $3,919.6M aggregate non-cash charges [S2]. All flow through GAAP operating income and to the GAAP net loss of $2,140M.

Underlying basis (company's preferred framing): excludes these impairments + restructuring charges + mark-to-market on commodity hedges + special items. Underlying EBITDA FY2025 ~$2.4B, underlying EPS ~$5.40 (consensus tracking estimate).

Quality verdict: GAAP loss is a true non-cash hit — equity book value reduced by ~$3.9B — but underlying cash-generative business is intact. For analytical purposes, use underlying figures for run-rate earnings power; use GAAP for full disclosure / equity-value-book-discipline check.

Cash Flow Conversion

[S1]

Cash conversion is consistently in the 70–80%+ range of underlying EBITDA — high-quality, well-correlated with reported underlying earnings.

Working Capital Discipline

[S1]

TAP runs negative working capital (payables > receivables + inventory) — typical for CPG with distributor-led downstream financing. No red flags; payables-driven cash management is stable.

Capex Discipline

Capex roughly tracks D&A — no aggressive growth-investment cycle; mostly maintenance + can-line modernization. 2026 guide $650M (also near D&A).

Capital Structure Quality

• Long-term debt $3.81B (2025) — down from $6.06B in 2024 (refinancing / paydown / reclassification effect; some moved to current liabilities — current liab jumped to $5.31B from $3.05B reflecting near-term maturities)
• Net debt $5.4B (per company), 2.3x underlying EBITDA — below stated target of <2.5x [S2]
• Investment-grade credit ratings (BBB / Baa2 area)
• Manageable maturity ladder

Adversarial Research Sweep

Short-seller reports: No active major short-seller report on TAP identified [S3][S4]. Hindenburg, Muddy Waters, Citron, Spruce Point: no published TAP coverage in recent years.

Litigation: Standard product-liability tail risk + ordinary-course commercial disputes; no material outstanding litigation flagged in FY2025 10-K beyond routine.

Regulatory investigations: None disclosed [S2][S3].

Quality-of-earnings flags:

1. Goodwill impairment trigger: The $3.65B Americas goodwill impairment in Q3 2025 was the principal QoE event. Triggered by softer-than-expected current-year results + lower long-term forecasts post-impairment-test [S2]. The market read this as honest reset of accounting carrying value vs. underlying operations.
2. Blue Run Spirits impairment ($75.3M, Q3 2025) — acquired 2023; growth target missed. Small relative to the package; signal: M&A discipline imperfect.
3. Staropramen partial impairment ($198.6M, Q3 2025) — softer CEE volumes; brand-equity reset.

Cash-EPS bridge: Underlying EPS ~$5.40 vs underlying FCF/share ~$5.40 (FCF $1,068M ÷ ~199M shares). They reconcile cleanly. No "earnings-without-cash" issue.

Revenue recognition / channel stuffing: Beer industry is volume-disclosed (HL shipped) — relatively hard to manipulate via revenue-recognition tricks. Distributor-channel inventory is monitored; TAP has not been flagged for channel-stuffing.

Pension / OPEB: Minor relative to size; no acute funding issue disclosed.

Hedge accounting: TAP uses commodity hedges (aluminum, barley, natural gas) and FX hedges. 2025 underlying-vs-GAAP reconciliation includes mark-to-market on non-designated hedges. Standard practice; not a red flag.

Adjusted Free Cash Flow Quality

Underlying FCF (using underlying definitions): roughly $1.0–1.1B annually 2024–2026. 2026 guide $1.1B ± 10% [S5]. This is the truest measure of capacity to fund dividend + buyback + de-leveraging.

4. Risks & Counter-Evidence

• Underlying-vs-GAAP gap is large in 2025 — management has flexibility in defining "underlying" — analyst should track quarter-by-quarter what adjustments are added and ensure they're truly non-recurring.
• Brand impairment risk continues: If US volumes decelerate further, ANOTHER goodwill impairment leg is possible (Americas goodwill now down to $1.95B vs $5.6B at YE2024; smaller cushion but not gone).
• Tax rate: 22–24% underlying ETR is consistent; no aggressive tax-planning red flag.

5. Decision / What I'm doing differently

Use underlying basis for forward modeling. Apply a conservative haircut to underlying EBITDA forecast (10–15%) in the bear case to account for the possibility of further impairments or unfavorable adjustment reclassifications. GAAP results in 2025 are not predictive of run-rate earnings power.

6. Open Questions

1. Will Q3 2026 (impairment-test annual cycle) trigger another non-cash charge? Watch volumes and pricing through H1 2026.
2. How does the $450M cost program show up in adjusted vs GAAP — will restructuring charges be excluded from underlying (the typical "add-back-then-take-credit" pattern)?

7. Source Index

• [S1] TAP_financials/xbrl/xbrl_summary.md
• [S2] Molson Coors Q3 2025 10-Q and 8-K; FY2025 10-K
• [S3] Web search — short-seller report scan (no major TAP coverage from Hindenburg/Muddy Waters/Citron/Spruce Point in trailing 3 years)
• [S4] WSJ / FT / Reuters litigation databases — no material flagged
• [S5] Molson Coors 2026 guidance — Feb 18, 2026 8-K